Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nintedanib vs placebo in progressive fibrosing ILD (China, Phase III)
CTR20211487Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of nintedanib in interstitial lung disease (ILD), sponsored by Boehringer Ingelheim. Started Jul 2021; status: completed.
02
Drugs
nintedanib
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on CTR20211487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211487.